Guilin South Pharmaceutical

Guilin South Pharmaceutical, a subsidiary of Fosun Pharma, is a prominent Chinese pharmaceutical manufacturer renowned for its pioneering work in antimalarial treatments. The company is the original developer of artesunate, which is recognized by the World Health Organization as the first-line treatment for severe malaria. Guilin South Pharmaceutical maintains a robust portfolio of WHO-prequalified products, including both injectable and oral artemisinin-based combination therapies (ACTs). Beyond antimalarials, the company produces a variety of generic medicines for cardiovascular and digestive health. With a strong focus on international markets, particularly in Africa, the company plays a critical role in global health initiatives through partnerships with organizations like the Medicines for Malaria Venture.